We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Losmapimod

News List

Fulcrum Begins of Losmapimod Trial for Hospitalized COVID-19 Patients americanpharmaceuticalreview
July 03, 2020
Fulcrum Therapeutics has received early notification from the U.S. Food and Drug Administration (FDA) that the company may proceed with initiating a Phase 3, randomized, double-blind, placebo-controlled trial of losmapimod in higher risk ...
Fulcrum to Evaluate Losmapimod as Potential COVID-19 Treatment americanpharmaceuticalreview
June 19, 2020
Fulcrum Therapeutics has announced plans to evaluate losmapimod as a potential treatment for patients with COVID-19.
Fulcrum acquires global rights of investigational drug losmapimod from GSK pharmaceutical-business-review
April 24, 2019
Fulcrum Therapeutics has acquired all worldwide development and commercialization rights of investigational drug losmapimod from GlaxoSmithKline (GSK).